Geneva based Andrew Alliance, has completed its series C funding round with $14 million investment from several leading life sciences enterprises. The startup developed an innovative approach for liquid handling with conventional laboratory pipettes.
The C-round investment brings together a strategic mix of globally recognized life sciences market leaders, along with private equity investors and including existing investors. Some of the participants in the round include; Tecan Group, the Waters Corporation, Inpeco, Rancilio Cube, Sam Eletr Trust and Omega Funds.
The Tecan Group is the world leader for automated liquid handling solutions, and Waters has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for nearly 60 years. Both companies are considered technology leaders in their respective fields.
“We are delighted to expand our team of investors and partners with the industry’s most recognized companies,” said Piero Zucchelli, CEO and a co-founder of Andrew Alliance. “It’s particularly meaningful that both Tecan and Waters appreciate how we’re making robotics accessible to more scientists.”
The startup will use the funds for continuous product innovation and strategic industry partnerships. It also will extend its close collaboration with customers worldwide to refine future offerings.
Pharma companies rely on Andrew
Andrew Alliance developed a liquid handling Robot “Andrew” to improve the repeatability, performance and speed of liquid handling in the pipetting process. Andrew eliminates human error, fatigue, and inhomogeneity in training which results in more reliable data.
Andrew Alliance’s flagship offering is a family of flexible, software-driven robot models, each with a footprint about the size of a standard piece of paper. The robots work right out of the box and deliver absolute consistency in how liquids are measured and tested, using standard pipettes and consumables. Andrew performs its job within a few minutes of setup.
“Andrew Alliance’s affordable benchtop robots using conventional pipettes are a new and complementary approach to Tecan’s workstations, which help customers to automate a wide variety of laboratory workflows in research and clinical diagnostics,” said David Martyr, CEO of Tecan.
In just four years, the startup has become the leading choice for life science bench robotics. To-date, 18 of the top 20 pharmaceutical companies, the top four diagnostic companies and 16 of the top 20 world’s leading academic research institutions rely on its solution.
(Press release/ran)
Please login or sign up to comment.
Commenting guidelines